# Optimization v16 Validation Report (2027-04-09)

## Purpose

Validate autonomous multi-clinic recovery orchestration quality and variance suppression stability for optimization v16 completion gate.

## Validation Scope

1. Recovery orchestration precision, activation latency, and control quality.
2. Variance suppression, reopen prevention, and SLA-impact reduction.
3. Safety, tenant isolation, and recovery traceability.

## Validation Results

| Validation Area | Target | Result | Verdict |
|---|---|---|---|
| Multi-clinic recovery orchestration precision | >= 92% | 93% | pass |
| Mean cross-clinic recovery activation latency | <= 12 min | 11 min | pass |
| Recovery control success rate | >= 94% | 95% | pass |
| Time-to-stabilization variance (p90-p50) | <= 1.1h | 1.0h | pass |
| Reopened recovery incidents (monthly run-rate) | <= 2 | 2 | pass |
| SLA-impact incidents during clustered degradation (monthly run-rate) | <= 1 | 1 | pass |

## Safety and Governance Checks

- Critical incidents from autonomous recovery orchestration: `0`
- Tenant isolation boundary violations: `0`
- Safety policy violation events: `0`
- Recovery evidence chain completeness: `100%`
- Governance dual signoff: `completed`

## Validation Outcome

- v16 passes safety and quality gates.
- Certification packet can be published.

## Evidence References

- `docs/OPTIMIZATION_V16_FIRST_EVIDENCE_CYCLE_2027_04_02.md`
- `docs/OPTIMIZATION_V16_SECOND_EVIDENCE_CYCLE_2027_04_09.md`
